Ferroptosis Inhibition and AMPK Activation: Soy Isoflavones Against Cerebral Injury

02 Apr 20264 min read0 viewsJournal Feed

GIST

Soy isoflavones (SI) were evaluated for neuroprotection in a rat model of cerebral ischemia–reperfusion injury induced by middle cerebral artery occlusion. SI pretreatment (120 mg/kg orally for 21 days) improved outcomes by reducing infarct size and brain edema and by improving neurological scores.

Biochemically, SI limited cerebral iron accumulation and modulated oxidative stress markers, lowering ROS and malondialdehyde while increasing glutathione and superoxide dismutase activities. Ferroptosis-related proteins showed a pattern consistent with ferroptosis suppression: decreased ACSL4 and increased GPX4, ACSL3, xCT, and ferritin (FTH/FTMT).

The protective effects were negated by the ferroptosis inducer RSL3, supporting a ferroptosis-dependent mechanism. SI also influenced energy sensing and redox regulation: MCAO reduced AMPK activation, which SI restored.

Pharmacologic inhibition of AMPK with compound C intensified ferroptotic injury and nullified SI benefits, whereas co-treatment with SI mitigated these adverse effects. Data indicate that SI confer neuroprotection in CIRI by activating AMPK signaling and inhibiting ferroptosis via modulation of iron handling, antioxidant defenses, and ferroptosis-associated proteins.

Uncertainty remains regarding translational applicability to humans.

Clinical Editorial

Summary

AMPK Activation and Ferroptosis Suppression as Mediators of Soy Isoflavone–Driven Neuroprotection

Background and aim

The study investigates whether soy isoflavones (SI) protect against cerebral ischemia–reperfusion injury (CIRI) by engaging AMPK signaling and inhibiting ferroptosis.
Ferroptosis and AMPK are positioned as relevant pathways for redox balance, iron handling, and lipid peroxidation in CIRI context.

Study design and population

Experimental model employed male Sprague–Dawley rats subjected to middle cerebral artery occlusion (MCAO) to simulate ischemic stroke.
SI were administered by gavage at 120 mg/kg daily for 21 days prior to MCAO.
Mechanistic validation included ferroptosis induction with RSL3 and AMPK inhibition with compound C.

Intervention and key endpoints

Primary outcomes comprised infarct size, brain water content, and functional scores (Longa, modified Neurological Severity Score).

Evidence for ferroptosis modulation

SI reduced iron accumulation in the brain and diminished oxidative stress markers.
Biochemical readouts showed lower malondialdehyde (MDA) with increased glutathione (GSH) and superoxide dismutase (SOD) activities.
Ferroptosis-related protein changes included decreased ACSL4 and increased GPX4, ACSL3, xCT, and ferritin (FTH/FTMT) expression, aligning with ferroptosis inhibition.
Functional protection by SI was negated by the ferroptosis inducer RSL3, supporting ferroptosis dependence of SI’s effects.

Evidence for AMPK involvement

MCAO reduced AMPK activation, an effect reversed by SI pretreatment (elevated p-AMPK/AMPK ratio).
Pharmacologic AMPK inhibition with compound C intensified ferroptotic injury and nullified SI benefits.
Co-treatment with SI reversed the adverse impact of AMPK inhibition, indicating SI acts through AMPK to mediate protection.

Context and limitations

The data support a model where SI confer neuroprotection in CIRI through an AMPK-dependent suppression of ferroptosis.
The report relies on a single animal model and predefined dosing; extrapolation to humans requires caution.
Not reported: clinical efficacy, long-term outcomes, dose–response nuance, and potential off-target effects.